- Posted on: 05/09/2011
- Deadline : 14/07/2015
- Active users : 1472
Summary of the technology
Each egg acts as a miniature bioreactor expressing your recombinant protein. We can express large numbers of protein variants or your other constructs rapidly and efficiently with our basic 3-step approach:
1. DESIGN the molecule, constructs, and expression strategy in order to maximise probability of a bioactive product that will meet your goals for structure, function, immunogenicity, enzymic activity, and ease of purification. Time: 2 weeks
2. Using the coding sequence (CDS) DNA for your desired product (or we can synthesize it for you), AdCEV™ DNA vector CONSTRUCTs are made. A full array of technologies ( foldons, tags, codon optimization, etc) can be incorporated in the construction of vectors to optimally express your molecule. Time: 4-6 weeks
3. We supply you with samples that can be examined by SDS PAGE, Western Blotting, RID, HI or any other assay as a first step in characterization. We can deliver material to you for testing.
Production of protein in eggs can be done with 2 eggs or 2000 eggs depending on your needs! Scale-up is simply a matter of using more eggs! Time:2-4 weeks
We offer genetic design services to improve your DNA, RNA or Protein molecular product. We rapidly design safe, effective bioproducts using our Computer Aided Gene Engineering (CAGE™) approach to create a new or improved biopharmaceutical product. We can support your vaccine or biologic product development all the way to full scale GMP manufacturing in eggs. We share the benefits of our international business and scientific experience through Consulting Services. Let us connect you to our network of knowledgeable individuals, and specialized companies, and help you enter the rapidly emerging arena of Global Health. Working with eggs offers easy scale-up, competitive yields, biosafety of your recombinant vaccine, biosimilar, diagnostic, rMAb etc. and potentially easy path to commercialization.
Description of the technology
Our inexpensive service allows you to rapidly evaluate the functions and quality of your desired recombinant protein, vaccine antigen, diagnostic reagent, therapeutic or rMAb protein expressed in hen eggs using a non GMO process.
Our AdCEV™/ Egg production platform uses fertilized hen eggs as a biological substrate for recombinant protein production. Working with eggs offers easy scale-up, competitive yields, and easy deployment as a small, medium, or large-scale Poultry Pharm™ solutions. Expressing your protein with AdCEV™ Vectors can provide an inexpensive way to produce milligram amounts of recombinant protein per egg in a production system that offers many attractive benefits including: -- Rapid cloning and expression. -- Potential for nilligrams of protein/egg. -- Short production time- 72 h. -- High fidelity eukaryotic post-translational processing. -- Simplified purification from allantoic fluid. -- Easy, rapid scale-up. with high level of biosafety for commercialization. You can rely on decades of vaccine manufacturing experience with eggs.
Main advantages of its use
- Rapid cloning and expression, Potential for nilligrams of protein/egg, Short production time- 72 h, High fidelity eukaryotic post-translational processing, Simplified purification from allantoic fluid, Easy, rapid scale-up. with high level of biosafety.
- Biosimilars and Biogenerics
- Diagnostic reagents
- Research reagents
- Therapeutic proteins
- Vaccine immunogens (inc. VLPs, conjugates, etc)
- Veterinary products
Additional information (attached documents)
About the vendor organization
AfriVax, Inc. is a U.S.A. corporation that researches, develops, and manufactures biopharmaceutical and biological products. The company's mission is to develop safe, efficacious vaccine, diagnostic, and therapeutic products to aid in the fight against global threats to human and animal health. Our mission is to make life-saving biomedical products and services easier to develop and manufacture anywhere in the world.
Technology from AfriVax, Inc.
Related Techs for Sale:
Techs for sale related to recombinant protein expression , recombinant protein , recombinant protein eggspression
Rare and Orphan Disease: Diseases with protein instability or missfolding (COMPUTATIONAL BIOLOGY AND DRUG DESIGN (School of Pharmacy) )Innovation of FBG - University of Barcelona / United States
Platform for the discovery of protein-protein or protein-ligand interaction modulators based on peptidomimetics (IPROTech)Innovation of Iproteos S.L. / United States
Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatise 1B (metabolic syndrome, diabetes and obesity)Innovation of University of Alcalá-OTRI / United States
Therapeutic effect of RHAMM (CD168) on type 1 and type 2 diabetes as well as on other autoimmune diseasesInnovation of Yissum - Research Development Company of the Hebrew University / United States
Method for the sequential immunochemical evaluation on a same biological sample of NCAM (Neural Cell Adhesion Molecule) protein and its PolySialic Acid (PSA) tail, by western blot coupled to chemiluminiscence detection.Innovation of University of Vigo / United States
Procedure for fast differentiation between transgenic and non-transgenic soybean using protein chromatographic profiles.Innovation of University of Alcalá-OTRI / United States
Techs for sale related to therapeutic , diagnostic reagent
About techs for sale
A Tech for Sale is the way Innoget clients promotes an innovative product, technology, method, process or service to get business and technology partners to contact them. Professionals like you can contact them if the product or technology is of your interest
Innoget is an open innovation marketplace for selling and buying technologies and knowledge. A global community comprised of thousands of professionals who have free access to Tech calls and Techs for sale posted by Innoget clients. Our clients are international organizations (companies and research centers.) convinced of the need to collaborate with external partners and actively seek to invest in joint development, technology acquisition, licensing or any other type of collaboration (open innovation). Via innoget.com our clients connect with companies, research institutions and innovation professionals worldwide. Organizations seeking innovation meet innovation-generating organizations. They capture external knowledge via publication of Tech calls and promote the knowledge generated within their organizations via publication of Techs for sale. By knowledge we understand innovative technologies, products, methods, procedures and services. The transfer of information is done confidentially between tech seekers and tech providers through the website. It is based on the information exchanged here that they decide to mantain contact offline